Considerations Developed for Administration of SRP-9001 Adverse Events in DMD

Published Date: 26 Mar 2023

A 12-member Dephi panel reviewed data from three clinical trials of delandistrogen maxeparvovec (SRP-9001; Sarepta) and made recommendations for the management of vomiting, myocarditis, acute liver failure and prevention of myositis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot